Literature DB >> 26792014

The Role of Ezetimibe in the Treatment of Cardiovascular Disease.

Anandita Agarwala1, Zaid Kajani2, Michael D Miedema3, Salim S Virani4,5,6.   

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.

Entities:  

Keywords:  Cardiovascular disease; Ezetimibe; Low-density lipoprotein cholesterol

Mesh:

Substances:

Year:  2016        PMID: 26792014     DOI: 10.1007/s11883-016-0560-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  30 in total

1.  Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.

Authors:  Christie M Ballantyne; Michael A Blazing; Thomas R King; William E Brady; Joanne Palmisano
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

2.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

Review 3.  Current therapy for patients with sitosterolemia--effect of ezetimibe on plant sterol metabolism.

Authors:  Kazumi Tsubakio-Yamamoto; Makoto Nishida; Yumiko Nakagawa-Toyama; Daisaku Masuda; Tohru Ohama; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2010-06-11       Impact factor: 4.928

4.  Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.

Authors:  Christie M Ballantyne; Nicola Abate; Zhong Yuan; Thomas R King; Joanne Palmisano
Journal:  Am Heart J       Date:  2005-03       Impact factor: 4.749

5.  Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.

Authors:  John J P Kastelein; Philip T Sager; Eric de Groot; Enrico Veltri
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

6.  Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.

Authors:  Brian A Ference; Faisal Majeed; Raju Penumetcha; John M Flack; Robert D Brook
Journal:  J Am Coll Cardiol       Date:  2015-03-11       Impact factor: 24.094

7.  Analyses of cancer data from three ezetimibe trials.

Authors:  Richard Peto; Jonathan Emberson; Martin Landray; Colin Baigent; Rory Collins; Robert Clare; Robert Califf
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

Review 8.  Study of Heart and Renal Protection (SHARP).

Authors:  Colin Baigent; Martin Landry
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

Review 9.  Sitosterolemia: diagnosis, investigation, and management.

Authors:  Joan Carles Escolà-Gil; Helena Quesada; Josep Julve; Jesús M Martín-Campos; Lídia Cedó; Francisco Blanco-Vaca
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

Review 10.  Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

Authors:  Erik S Stroes; Paul D Thompson; Alberto Corsini; Georgirene D Vladutiu; Frederick J Raal; Kausik K Ray; Michael Roden; Evan Stein; Lale Tokgözoğlu; Børge G Nordestgaard; Eric Bruckert; Guy De Backer; Ronald M Krauss; Ulrich Laufs; Raul D Santos; Robert A Hegele; G Kees Hovingh; Lawrence A Leiter; Francois Mach; Winfried März; Connie B Newman; Olov Wiklund; Terry A Jacobson; Alberico L Catapano; M John Chapman; Henry N Ginsberg
Journal:  Eur Heart J       Date:  2015-02-18       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.